Journals / Türk Kardiyoloji Derneği Arşivi / 2017 / Cilt: 45 - Sayı: 5

Type 1 neurofibromatosis complicated by pulmonary arterial hypertension: a case report

Pulmoner hipertansiyon ile komplike olan tip 1 nörofibromatozis

Pages
458–461
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Presently described is a case of neurofibromatosis complicated by pulmonary hypertension.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neurofibromatosis type I (NF1) is a rare genetic disease caused by mutations in the NF1 gene, which encodes the tumor suppressor neurofibromin.
📊
Key Findings & Data:Precapillary pulmonary hypertension is a severe complication of NF1, initially described in patients with advanced parenchymal lung disease, which may complicate the course of NF1.
💡
Conclusion & Impact:Presently described is a case of neurofibromatosis complicated by pulmonary hypertension.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neurofibromatosis type I (NF1) is a rare genetic disease caused by mutations in the NF1 gene, which encodes the tumor suppressor neurofibromin. Precapillary pulmonary hypertension is a severe complication of NF1, initially described in patients with advanced parenchymal lung disease, which may complicate the course of NF1. Presently described is a case of neurofibromatosis complicated by pulmonary hypertension.

Özet

Nörofibromatozis tip 1 (NF1), tümör süpresor nörofib- romini kodlayan NF1 geninde mutasyonların sonucu ortaya çıkan nadir bir genetik hastalıktır. Prekapiller pulmoner hi- pertansiyon, ileri parankimal akciğer hastalığı olan hastalar- da tanımlanmış olup, hastalığın seyrini olumsuz etkileyebi- lir. Bu yazıda pulmoner hipertansiyon ile komplike olmuş bir nörofibromatosis hastası sunuldu.

🔖

Cite This Article

ÖNCEL, C. R., UÇAR, M., YILDIRIM, A. B., KÜÇÜK, M. (2022). Type 1 neurofibromatosis complicated by pulmonary arterial hypertension: a case report. Türk Kardiyoloji Derneği Arşivi, Cilt: 45 - Sayı: 5, 458–461. https://ajindex.com/articles/632355

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Reynolds RM, Browning GG, Nawroz I, Campbell IW. Von Recklinghausen's neurofibromatosis: neurofibromatosis type 1. Lancet 2003; 361:1552-54
  2. Oderich GS, Sullivan TM, Bower TC, Gloviczki P, Miller DV, Babovic-Vuksanovic D, et al. Vascular abnormalities in pa?tients with neurofibromatosis syndrome type I: clinical spec?trum, management, and results. J Vasc Surg 2007;46:475-84
  3. Malviya A, Mishra S, Kothari SS. Type 1 neurofibromatosis and pulmonary hypertension: a report of two cases and a re?view. Heart Asia 2012;4:27-30
  4. Lie JT. Vasculopathies of neurofibromatosis type 1 (von Recklinghausen disease). Cardiovasc Pathol 1998;7:97-108
  5. National Institutes of Health Consensus Development Conference Statement: Neurofibromatosis. Arch Neurol 1988;45:575-78
  6. Stewart DR, Cogan JD, Kramer MR, Miller WT, Christiansen LE, Pauciulo MW, et al. Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopa?thy? Chest 2007;132:798-808
  7. Jett K, Friedman JM. Clinical and genetic aspects of neurofi?bromatosis 1. Genet Med 2010;12:1-11
  8. Friedman JM, Arbiser J, Epstein JA, Gutmann DH, Huot SJ, Lin AE, et al. Cardiovascular disease in neurofibromatosis 1: report of the NF1 cardiovascular task force. Genet Med 2002;4:105-11
  9. Rich S. Clinical insights into the pathogenesis of primary pul?monary hypertension. Chest 1998;114:237-41
  10. Yuan JX, Aldinger AM, Juhaszova M, Wang J, Conte JV, Gaine SP, et al. Dysfunctional voltage-gated K1 channels in pulmonary artery smooth muscle cells of patients with pri?mary pulmonary hypertension. Circulation 1998;98:1400-6
  11. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension.The task force for the diagnosis and treatment of pulmonary hypertension of the European so?ciety of cardiology (ESC) and the European Respiratory Soci?ety (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493- 537.